Rahul joined Polaris Partners in 2021 and serves as an entrepreneur partner. He is a biotech executive and physician-scientist, founding and building biotechnology companies as well as working as a practicing physician.
Most recently, Rahul was Chief Executive Officer at Pandion Therapeutics, a company focused on therapeutics for autoimmune and inflammatory diseases, which he led from Series A through its clinical transition, initial public offering and its ultimate acquisition by Merck for $1.85B. Prior to joining Pandion, Rahul founded Corvidia Therapeutics, a precision cardiovascular company, where he served as Chief Medical Officer and Chief Strategy Officer. Corvidia Therapeutics was acquired by Novo Nordisk for $2.1B. Across his companies, Rahul has led fundraising totaling over $300M to date. Prior to Corvidia, Rahul served as a director in the Emerging Innovations Unit at AstraZeneca, where he was recognized with the AstraZeneca Leadership Recognition Award.
Rahul continues to practice cardiovascular medicine at the Brigham and Women’s Hospital in Boston, and is a lecturer in medicine at Harvard Medical School.
Rahul received his B.A. Cum Laude from Tufts University where he was a member of the Golden Key National Honor Society, and M.D. from the Tufts University School of Medicine, where he was the recipient of the Louis Weinstein Prize in Clinical Medicine and was inducted into the Alpha Omega Alpha Honor Society as a junior. He also served as an Albert Schweitzer Fellow.
The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.